pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda recalls·Jul 18·3 min read
save

Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine

FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg to the consumer level due to cross contamination with Ranitidine.

Jul 18, 2026·read at fda recalls ↗

Summary Company Announcement Date: July 18, 2026 FDA Publish Date: July 20, 2026 Product Type: Drugs Reason for Announcement: Recall Reason Description Potential cross contamination with Ranitidine Company Name: Unique Pharmaceutical Laboratories Brand Name: Brand Name(s) Rising Pharma Holdings Inc. Product Description: Product Description Cetirizine Hydrochloride Tablets USP 5 mg Company Announcement FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J.

B. Chemicals & Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg to the consumer level due to cross contamination with Ranitidine.Risk Statement: For consumers with a hypersensitivity to the ingredients in ranitidine, there is a reasonable probability that ingestion of Cetirizine tablets contaminated with ranitidine could result in serious adverse events including severe hypersensitivity reactions and anaphylaxis that manifests as hypotension, dyspnea, difficulty swallowing, throat and facial edema, generalized pruritic, urticaria, and loss of consciousness, which are all life-threatening. To date, Unique Pharmaceuticals has not received any reports of adverse events related to this recall.The product is used as an Antihistamine and is packaged in HDPE Bottle pack of 100 tablets (NDC: 16571-401-10).Product complaint received that a pharmacy technician identifies the discrepancy while counting the tablets at the time of dispensing.

A product complaint reported about Appearance of red dot on Tablets of Cetirizine Hydrochloride Tablets USP 5 mg and some tablets are discolored (Appeared as discolored due to multiple red colored dots on tablets).The product subject to this recall is listed below and packaged in HDPE bottles. The product can be identified by reviewing the product name, manufacturer details and lot number displayed on the bottle. Product was distributed Nationwide to several wholesalers/retailers.NDCManufacturerDistributed ByProduct DescriptionLotNumbersExpiration Date16571-401-10Unique Pharmaceutical Laboratories (A Div.

of J.B. Chemicals &Pharmaceuticals Ltd.)Rising Pharma Holdings Inc.Cetirizine Hydrochloride Tablets USP 5 mg, Pack 100’s HDPE containerGY82502910/202816571-401-10Unique Pharmaceutical Laboratories (A Div. of J.B.

Chemicals &Pharmaceuticals Ltd.)Rising Pharma Holdings Inc.Cetirizine Hydrochloride Tablets USP 5 mg, Pack 100’s HDPE containerGY82503010/202816571-401-10Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals &Pharmaceuticals Ltd.)Rising Pharma Holdings Inc.Cetirizine Hydrochloride Tablets USP 5 mg, Pack 100’s HDPE containerGY82503110/202816571-401-10Unique Pharmaceutical Laboratories (A Div.

of J.B. Chemicals &Pharmaceuticals Ltd.)Rising Pharma Holdings Inc.Cetirizine Hydrochloride Tablets USP 5 mg, Pack 100’s HDPE containerGY82503210/2028Unique Pharmaceuticals has notified its distributor Rising Pharma Holdings Inc. (2 Tower Center Blvd., Suite 1401A, East Brunswick, NJ 08816) who has notified its distributors and direct customers by email and is arranging for the return of all recalled products.Consumers with general or medical inquiries regarding this recall can contact Rising Pharma Holdings Inc.

at: Phone number: 1-844-874-7464 8:00 a.m. to 5:00 p.m. (EST), (Monday-Friday) or e-mail address: pv@risingpharma.com or qa@risingpharma.com.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.Complete and submit the report Online: www.fda.gov/medwatch/report.htm1Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Company Contact Information Consumers: Rising Pharma Holdings Inc.

1-844-874-7464 pv@risingpharma.com or qa@risingpharma.com Product Photos

source

Reporting by fda recalls.

read at fda recalls ↗
556 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5d agoSunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matterfda recalls
  • 5d agoBAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTIONfda recalls
  • 5d agoAmerican Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matterfda recalls
  • 5d agoLIDL US Recalls Eridanous Shortbread Cookies with Chocolate Truffle Coating & Apricot Filling due to Undeclared Wheat, Soy, Milk, and Eggsfda recalls
  • 6d agoMidwest Poultry Services. L.P. Recalls Shell Eggs Due to Possible Salmonella Enteritidis Contaminationfda recalls